Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Pramlintide
A synthetic amylin analogue approved as an add-on in insulin-treated diabetes.
Cagrilintide
A long-acting amylin analogue, now in its own Phase 3 programme as well as in combination therapy.
How far human research has progressed
Pramlintide
Approved adjunct medicine with long post-marketing historyCagrilintide
Phase 3 (RENEW) as monotherapy; also studied within a fixed-dose combinationClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Pramlintide
Not separately assessed; see the full profile.Cagrilintide
Not separately assessed; see the full profile.Human research context
Pramlintide
Approved adjunct medicine with long post-marketing historyCagrilintide
Phase 3 (RENEW) as monotherapy; also studied within a fixed-dose combinationHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Pramlintide
Cagrilintide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Pramlintide
Cagrilintide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Pramlintide
Cagrilintide
Regulatory status (legal position, not proof it works)
Pramlintide
Named regulators: FDA (US)
FDA-approved (Symlin) as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin and have not achieved adequate control. Approval is specific to that adjunctive role.
Cagrilintide
Check jurisdiction-specific details in the profile.
Investigational and not approved anywhere. Standalone cagrilintide has entered the RENEW Phase 3 programme. It is also one half of CagriSema, a separate fixed-dose combination with semaglutide — the combination has its own trials and its own regulatory filing, and results do not transfer between them. FDA states explicitly that cagrilintide cannot be used in compounding under US federal law, because it is not an FDA-approved drug and is not on a bulk drug substances list permitted for compounding. That is a compounding and legal-status point about US supply routes — it is not a finding about how well cagrilintide works, and not a new intrinsic-toxicity finding about the molecule.
Common claims
Pramlintide
- · Improves post-meal glucose control as an insulin adjunct
- · Modest weight effects in studied populations
Cagrilintide
- · Adds weight loss on top of GLP-1 therapy
- · Different satiety pathway, additive effect
How settled our evidence rating is
Pramlintide
Cagrilintide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Pramlintide
No established human cancer signal within approved use.Cagrilintide
No established human cancer signal. Not a primary safety question for this compound.What this adds up to, in plain English
Pramlintide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Cagrilintide
Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.A comparison is not a recommendation